Cocrystal Pharma, Inc. (COCP) Misses Q3 EPS by 19c Nov 14, 2025 05:10PM
Cocrystal Pharma, Inc. (COCP) files for 5.74M share offering by selling stockholders Sep 19, 2025 04:34PM
Cocrystal Pharma presents CDI-988 oral norovirus antiviral data at conference Sep 12, 2025 08:02AM
Cocrystal Pharma gets FDA clearance for norovirus drug study Sep 8, 2025 08:04AM
Cocrystal Pharma, Inc. (COCP) PT Lowered to $6 at H.C. Wainwright Jun 20, 2025 06:35AM


May 29, 2025 08:02AM Cocrystal's (COCP) Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
May 15, 2025 05:00PM Cocrystal Pharma, Inc. (COCP) Misses Q1 EPS by 23c
Jan 8, 2025 08:01AM Cocrystal Pharma (COCP) Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Dec 31, 2024 08:00AM Cocrystal Pharma, Inc. (COCP) to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
Nov 13, 2024 04:24PM Cocrystal Pharma, Inc. (COCP) Misses Q3 EPS by 49c
Sep 26, 2024 08:03AM Cocrystal Pharma (COCP) Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
Aug 22, 2024 06:34AM Cocrystal Pharma, Inc. (COCP) PT Lowered to $7 at H.C. Wainwright
Aug 15, 2024 03:00PM CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
Aug 15, 2024 06:15AM Cocrystal Pharma, Inc. (COCP) Misses Q2 EPS by 53c
Jul 18, 2024 08:07AM Cocrystal Pharma (COCP) Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor